|
Feb 15
|
Mithra sells shares in Mayne Pharma
|
|
Dec 21
|
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
|
|
Dec 20
|
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
|
|
Dec 4
|
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China
|
|
Nov 30
|
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States
|
|
Nov 28
|
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam
|
|
Nov 7
|
Mithra’s NEXTSTELLIS® granted additional patent in the United States
|
|
Nov 6
|
Mithra releases invitation to its extraordinary securities holders’ meeting
|
|
Aug 28
|
Mithra completes EUR 20 million private placement in equity. Update of total number of voting rights (denominator)
|
|
Jul 17
|
Notice of Adjustment of the Conversion Price of Mithra's EUR 125,000,000 Senior Unsecured Convertible Bonds due 2025
|